Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Corcept Therapeutics (CORT) Cost of Revenue (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Cost of Revenue for 15 consecutive years, with $2.9 million as the latest value for Q1 2026.

  • For Q1 2026, Cost of Revenue rose 19.98% year-over-year to $2.9 million; the TTM value through Mar 2026 reached $13.5 million, up 25.18%, while the annual FY2025 figure was $13.0 million, 19.25% up from the prior year.
  • Cost of Revenue hit $2.9 million in Q1 2026 for Corcept Therapeutics, up from $2.5 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $4.6 million in Q3 2025 and bottomed at $1.2 million in Q1 2022.
  • Average Cost of Revenue over 5 years is $2.3 million, with a median of $2.4 million recorded in 2025.
  • Year-over-year, Cost of Revenue surged 82.9% in 2024 and then fell 13.9% in 2025.
  • Corcept Therapeutics' Cost of Revenue stood at $1.5 million in 2022, then increased by 26.82% to $1.9 million in 2023, then soared by 57.49% to $3.0 million in 2024, then dropped by 13.9% to $2.5 million in 2025, then rose by 13.28% to $2.9 million in 2026.
  • According to Business Quant data, Cost of Revenue over the past three periods came in at $2.9 million, $2.5 million, and $4.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.